Loading stock data…
CLYM
$11.93+0.48 (+4.19%)
Market OpenUpdated 10:20 AM EDT
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Climb Bio, Inc. in the Healthcare sector is trading at $11.45. The stock is currently near its 52-week high of $11.49, remaining 181.3% above its 200-day moving average. Technical signals show overbought RSI of 76 and bullish MACD crossover, explaining why CLYM maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 76) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.93
Potential Upside
5%
Whystock Fair Value$12.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$634.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.30%
Volume
Today's trading volume
322,076
Recent News
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE
Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion and to provide updates on development plans and timelines for its lead candidate, budoprutug, across primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement expected to yield approximately $110 million in gross proceeds. The financing involves the sale of 9,481,000 shares of common stock at $9.50 per […]
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026
Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining an Outperform rating on the shares. The rating update came ahead of the upcoming clinical reveals, which will reveal how subcutaneous […]
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease
Climb Bio Inc (NASDAQ:CLYM) is one of the tiny stocks that are on fire right now. On April 7, Climb Bio received FDA Fast Track Designation for budoprutug, its investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy/pMN. This designation is intended to expedite the development and review of drugs that treat serious […]
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?
Climb Bio Inc (NASDAQ:CLYM) is one of the must-buy small cap stocks to buy. On April 7, BTIG reaffirmed its Buy rating and $8 price target on Climb Bio Inc (NASDAQ:CLYM). The investment bank made the move after Climb announced it had received FDA Fast Track Designation for its lead drug candidate, budoprutug. Budoprutug is […]